Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02067156 · ClinicalTrials.gov registry record · Phase 2
Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma
A Phase 2 study, sponsored by GenSpera.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02067156 is a Phase 2 study that has completed, run by GenSpera. The registered enrollment target is 26 participants.
The verdict
NCT02067156, a Phase 2 study, has completed, sponsored by GenSpera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
This study will evaluate if a drug called G-202 can be safely used to treat people with glioblastoma (GBM) that has progressed or recurred. G-202 is given by intravenous infusion on three consecutive days of a 28-day cycle.
Interventions
- DRUG G-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-02 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02067156
The ClinicalTrials.gov registry entry for NCT02067156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GenSpera, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which G-202 is the first listed.
NCT02067156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02067156 about?
NCT02067156 is a clinical study titled "Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma". This study will evaluate if a drug called G-202 can be safely used to treat people with glioblastoma (GBM) that has progressed or recurred. G-202 is given by intravenous infusion on three consecutive days of a 28-day cycle.
What is the current status of trial NCT02067156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2014-02. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02067156?
The interventions under investigation include: G-202 (DRUG).
Who is sponsoring clinical trial NCT02067156?
This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.